Emiel De Jaeghere

Journal Article
A1
open access

Circulating immune cell profiling in advanced cervical and endometrial cancer patients treated with PD-1 blockade, radiotherapy, and immune modulation in the PRIMMO trial

Regina Esi Mensimah Baiden-Amissah, Sandra Tuyaerts, Daniela Annibali, Alejandro Herreros-Pomares, Wout De Wispelaere, Rossana Maria Benedetto, Emiel De Jaeghere (UGent) , An M. T. Van Nuffel, Peter Vuylsteke, Stéphanie Henry, et al.

(2026) FRONTIERS IN IMMUNOLOGY. 17.

Add to list

Exploiting the synergistic effect of PARP inhibition with cisplatin and hyperthermia during interval cytoreductive surgery and HIPEC in ovarian cancer : the PROOV study : a phase I/II clinical trial

Leah J. Frenkel, Madelief Schreuder Goedheijt, Carolina Velazquez, Marta Lopez-Yurda, Daniela Annibali, Frans I. Opdam, Emiel De Jaeghere (UGent) , Alicia Leon Del Castillo, Maaike P.G. Vreeswijk, Christianne Lok, et al.

(2026) INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. In International Journal of Gynecological Cancer 36(2, Supplement 1).

Add to list

Journal Article
A1
open access

Quality of life measures in advanced endometrial cancer : a systematic review of reporting practices in phase III clinical trials

Justine Himpe (UGent) , Marjolein Orije (UGent) , Emiel De Jaeghere (UGent) , Katrien Vandecasteele (UGent) and Hannelore Denys (UGent)

(2026) CANCERS. 18(2).

Add to list

Miscellaneous

Doubting T(h)OMAS : has the era of precision oncology arrived in uterine leiomyosarcoma?

Emiel De Jaeghere (UGent) , A. Dufresne, L. Azarang and W.T.A. van der Graaf

(2026) ANNALS OF ONCOLOGY. 37(4). p.439-441

Add to list

PhD Thesis
open access

Immune checkpoint inhibitors in gynecologic cancer : getting to prime T(I)ME?

Emiel De Jaeghere (UGent)

(2025)

Add to list

Miscellaneous
open access

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study (vol 72, pg 475, 2022)

Emiel De Jaeghere (UGent) , Sandra Tuyaerts, An M. T. Van Nufel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens (UGent) , Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, et al.

(2024) CANCER IMMUNOLOGY IMMUNOTHERAPY. 74(1).

Add to list

Journal Article
A1
open access

Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab : insights from the phase II PRIMMO trial

Emiel De Jaeghere (UGent) , Hannelore Hamerlinck (UGent) , Sandra Tuyaerts, Lien Lippens (UGent) , An M.T. Van Nuffel, Regina Baiden-Amissah, Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, Peter A. van Dam, et al.

(2024) GYNECOLOGIC ONCOLOGY. 191. p.275-286

Add to list

Journal Article
A1
open access

Identification of potentially actionable genetic variants in epithelial ovarian cancer : a retrospective cohort study

Charlotte Fieuws, Joni Van der Meulen (UGent) , Kristiaan Proesmans (UGent) , Emiel De Jaeghere (UGent) , Siebe Loontiens (UGent) , Jo Van Dorpe (UGent) , Philippe Tummers (UGent) , Hannelore Denys (UGent) , Koen Van de Vijver (UGent) and Kathleen Claes (UGent)

(2024) NPJ PRECISION ONCOLOGY. 8(1).

Add to list

Sexual health in Belgian cervical cancer survivors : an exploratory qualitative study

Eline Naert (UGent) , Hans Van Hulle, Emiel De Jaeghere (UGent) , Marjolein Orije (UGent) , Sarah Roels, Rawand Salihi (UGent) , Koen J. Traen, Kristien Watty, Lise-Marie Kinnaer (UGent) , Hans Verstraelen (UGent) , et al.

(2024) QUALITY OF LIFE RESEARCH. 33(5). p.1401-1414

Add to list

A breath of relief : navigating the resolution of unexplained respiratory failure

Thor Hautekiet, Emiel De Jaeghere (UGent) , Nina Cardinaels (UGent) , Yannick Vande Weygaerde (UGent) , Dieter Stevens (UGent) , Eric Derom (UGent) and Pieter Depuydt (UGent)

(2023) Belgian Pneumology Days 2023, Abstracts. In Belgian Pneumology Days

Academic Bibliography

Emiel De Jaeghere

Circulating immune cell profiling in advanced cervical and endometrial cancer patients treated with PD-1 blockade, radiotherapy, and immune modulation in the PRIMMO trial

Exploiting the synergistic effect of PARP inhibition with cisplatin and hyperthermia during interval cytoreductive surgery and HIPEC in ovarian cancer : the PROOV study : a phase I/II clinical trial

Quality of life measures in advanced endometrial cancer : a systematic review of reporting practices in phase III clinical trials

Doubting T(h)OMAS : has the era of precision oncology arrived in uterine leiomyosarcoma?

Immune checkpoint inhibitors in gynecologic cancer : getting to prime T(I)ME?

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study (vol 72, pg 475, 2022)

Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab : insights from the phase II PRIMMO trial

Identification of potentially actionable genetic variants in epithelial ovarian cancer : a retrospective cohort study

Sexual health in Belgian cervical cancer survivors : an exploratory qualitative study

A breath of relief : navigating the resolution of unexplained respiratory failure

Contents

Support

Contact